News
Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.
Exopharm (ASX:EX1) is pursuing a product pipeline-driven platform strategy. Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.
Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.
Exopharm’s exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.
Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.
Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.
In addition, Exopharm is using its technology platform to enable its own product development programs – each aimed at delivering a transformative medicine for an unmet medical need.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
CLOSING BELL: Corruption? In Africa? Over mining licences? That can’t be right, surely…
News
CLOSING BELL: ‘How to falter at the last furlong and limp home like a beaten favourite’, by the ASX
News
ASX February Winners: Semiconductor stocks shine in tough month for investors
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Forcing the product to pay to be the product is about as Meta as it gets
News
ASX Small Caps Lunch Wrap: Who wants to watch China pull a CEO out of its hat today?
News
Rise and Shine: everything you need to know before the ASX opens
News
Weekly Small Cap and IPO wrap: Large and small caps stumble this week, Omnia Metals due diligence pays off
News
CLOSING BELL: If everything could just stop blowing up for a while, that’d be great.
Health & Biotech
Planets align as Exopharm advances its technologies and experts report that exosomes may hold the key to mRNA therapeutics
Health & Biotech
Exopharm makes big LEAP moving to Phase 2 of collaborative agreement with AIRM
News
ASX Quarterlies: Nuheara rockets 33pc, Dicker continues to grow, while these biotechs are all cashed up
Experts
THE SUNDAY ROAST: The ASX small caps that lit a fire under Stockhead’s experts this week.
Experts
MoneyTalks: Two reasons why today’s Aussie biotech sector is like the ’90s scramble for beachside property
Health & Biotech
Exopharm identifies two new lead programs as exosomes gain prominence in gene therapy
Health & Biotech
Exopharm a LEAP ahead of competitors in emerging exosome medicine field
News